Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.
MetadataShow full item record
A beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the ‘amyloid hypothesis’, the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance its clearance. Some have progressed to human trials, however all have failed to improve cognition in patients. This has led researchers to question whether Aβ is really the problem. However, the trials have been targeting end stages of AD, by which stage extensive irreversible neuronal damage has already occurred. Intervention is required preclinically, therefore preclinical AD biomarkers are needed. In this regard, amyloid imaging and cerebrospinal fluid biomarkers are leading the way, with plasma biomarkers and eye tests also being investigated. This review covers the current state of knowledge of Aβ as an early diagnostic biomarker and as a therapeutic target in AD.
Showing items related by title, author, creator and subject.
Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subsetChatterjee, P.; Gupta, V.; Fagan, A.; Jasielec, M.; Xiong, C.; Sohrabi, H.; Dhaliwal, Satvinder; Taddei, K.; Bourgeat, P.; Brown, B.; Benzinger, T.; Bateman, R.; Morris, J.; Martins, R. (2015)Introduction: This study examines platelet amyloid precursor protein (APP) isoform ratios of 120KDa to 110KDa (APPr) between mutation carriers (MC) carrying a mutation for autosomal dominant Alzheimer's disease (ADAD) and ...
Associations between gonadotropins, testosterone and [beta] amyloid in men at risk of Alzheimer’s diseaseVerdile, Giuseppe; Laws, S.; Henley, D.; Ames, D.; Bush, A.; Ellis, K.; Faux, N.; Gupta, V.; Li, Q.; Masters, C.; Pike, K.; Rowe, C.; Szoeke, C.; Taddei, K.; Villemagne, V.; Martins, R. (2014)Testosterone and gonadotropins have been associated with cognitive decline in men and the modulation of β amyloid (Aβ) metabolism. The relatively few studies that have investigated whether changes in one or a combination ...
Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort StudiesMartins, R.; Villemagne, V.; Sohrabi, H.; Chatterjee, P.; Shah, T.; Verdile, Giuseppe; Fraser, P.; Taddei, K.; Gupta, V.; Rainey-Smith, S.; Hone, E.; Pedrini, S.; Lim, W.; Martins, I.; Frost, S.; Gupta, S.; O'Bryant, S.; Rembach, A.; Ames, D.; Ellis, K.; Fuller, S.; Brown, B.; Gardener, S.; Fernando, B.; Bharadwaj, Prashant; Burnham, S.; Laws, S.; Barron, A.; Goozee, K.; Wahjoepramono, E.; Asih, P.; Doecke, J.; Salvado, O.; Bush, A.; Rowe, C.; Gandy, S.; Masters, C. (2018)Â© 2018-IOS Press and the authors. All rights reserved. Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost ...